LAT1 and Lung Cancer Prognosis
Author Information
Author(s): Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M
Primary Institution: Gunma University Graduate School of Medicine
Hypothesis
The study aims to evaluate the prognostic value of LAT1 in patients with nonsmall cell lung cancer (NSCLC).
Conclusion
LAT1 expression is a significant factor for predicting poor prognosis in patients with resectable stage I–III NSCLC.
Supporting Evidence
- 51% of patients showed positive LAT1 expression.
- The 5-year survival rate for LAT1-positive patients was 51.8%, significantly worse than 87.8% for LAT1-negative patients.
- LAT1 expression was significantly associated with lymph node metastasis and disease stage.
- Multivariate analysis confirmed LAT1 as an independent factor for predicting poor prognosis.
Takeaway
This study found that a protein called LAT1 can help doctors predict how well patients with lung cancer might do after treatment.
Methodology
The study reviewed 321 patients with completely resected pathologic stage I–III NSCLC and evaluated LAT1 expression and Ki-67 labelling index through immunohistochemical staining.
Participant Demographics
196 men and 125 women, aged 39 to 84 years, with a mean age of 67 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website